The United States filed a complaint under the False Claims Act (FCA) against Regeneron Pharmaceuticals Inc. (Regeneron), a New York-based pharmaceutical company. Regeneron manufactures and sells Eylea, an anti-vascular endothelial growth factor inhibitor approved by the Food and Drug Administration to treat, among other conditions, neovascular Age-Related Macular Degeneration, a prevalent, usually age-related condition that impairs vision. Read More
Home » False Claims Act Complaint Filed Against Regeneron Pharmaceuticals for Fraudulent Drug Pricing Reporting
False Claims Act Complaint Filed Against Regeneron Pharmaceuticals for Fraudulent Drug Pricing Reporting
Related Posts
Air Force Employee Pleads Guilty to Conspiracy to Disclose Unlawfully
A civilian employee of the U.S. Air Force assigned to the U.S. Strategic Command (USSTRATCOM) at Offutt Air Force Base pleaded guilty today to conspiring… BronAir Force Employee Pleads Guilty to Conspiracy to Disclose Unlawfully
Two Former West Virginia Correctional Officers Sentenced on Federal
Two former correctional officers from the Southern Regional Jail in Beaver, West Virginia, were sentenced today for their roles in an assault that resulted in… BronTwo Former West Virginia Correctional Officers Sentenced on Federal
Tennessee Man Pleads Guilty to COVID-19 Employee Retention Credit
A Tennessee man pleaded guilty to conspiring to commit wire and mail fraud, aiding and assisting in the preparation of a false tax return, and… BronTennessee Man Pleads Guilty to COVID-19 Employee Retention Credit